Biogen director Lloyd Minor sells 1,186 shares
Biogen Inc. director Lloyd Minor reported selling a total of 1,186 shares of Biogen common stock in two open-market or private transactions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Biogen Inc. director Lloyd Minor reported selling a total of 1,186 shares of Biogen common stock in two open-market or private transactions. On 3 August 2026 he sold 593 shares at $203.34 per share, and on 4 August 2026 he sold 593 shares at $200.96 per share.
The trades involve non-derivative common stock held directly and are affirmed as having been executed under a Rule 10b5-1 trading plan.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 593 | $200.96 | $119K |
| Sale | Common Stock | 593 | $203.34 | $121K |
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
open market or private transaction financial
non-derivative financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Biogen (BIIB) director Lloyd Minor report?
Were Lloyd Minor’s Biogen (BIIB) stock sales made under a Rule 10b5-1 plan?
What type of security did Lloyd Minor sell in Biogen (BIIB)?
AI-generated analysis. How Rhea-AI works. Not financial advice.